Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.

Matthias BrendelMaximilian DeussingTanja BlumeLena KaiserFederico ProbstFelix OverhoffFinn PetersBarbara von Ungern-SternbergSergey RyazanovAndrei LeonovChristian GriesingerAndreas ZwergalJohannes LevinPeter BartensteinIgor YakushevPaul CummingGuido BoeningSibylle ZieglerJochen HermsArmin GieseAxel Rominger

Published in: Alzheimer's research & therapy (2019)

Late-stage oligomer modulation effectively ameliorated tau pathology in hTau mice and rescued metabolic function. Molecular imaging by FDG-PET can serve for monitoring effects of Anle138b treatment.

Keyphrases

mouse model
cerebrospinal fluid
endothelial cells
positron emission tomography
pet ct
computed tomography
type diabetes
cognitive decline
combination therapy